iNtRON Biotechnology인트론바이오
048530 · KOSDAQ · ₩048530 · 인트론바이오
₩3,050 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩5.7B | ₩6.4B | ₩9.6B | ₩14B | ₩29B |
| Cost of sales | ₩2.6B | ₩2.7B | ₩3.7B | ₩4.3B | ₩7.5B |
| Gross profit | ₩3.1B | ₩3.7B | ₩5.8B | ₩9.7B | ₩22B |
| Operating income | −₩7.9B | −₩5.2B | −₩3.2B | −₩1.3B | ₩10B |
| Net income | −₩8.9B | −₩2.4B | −₩11B | ₩5.7B | ₩9.9B |
| Net income to shareholders | −₩8.9B | −₩2.4B | −₩11B | ₩5.7B | ₩9.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩74B | ₩86B | ₩98B | ₩142B | ₩154B |
| Current assets | ₩43B | ₩51B | ₩60B | ₩113B | ₩124B |
| Cash and equivalents | ₩26B | ₩33B | ₩40B | ₩25B | ₩74B |
| Total liabilities | ₩4.4B | ₩2.5B | ₩1.8B | ₩35B | ₩52B |
| Current liabilities | ₩4.1B | ₩1.3B | ₩786M | ₩32B | ₩33B |
| Borrowings | ₩3B | ₩861M | ₩0 | ₩20B | ₩20B |
| Total equity | ₩70B | ₩84B | ₩96B | ₩107B | ₩102B |
| Shareholders' equity | ₩70B | ₩84B | ₩96B | ₩107B | ₩102B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩5.2B | −₩136M | ₩3.2B | ₩6.1B | ₩17B |
| Free cash flow | −₩5.2B | −₩136M | ₩3.2B | ₩6.1B | ₩17B |
| Dividends paid | ₩3.2B | ₩3.3B | — | — | — |
Consolidated where available. Amounts in won.
Also known as: iNtRON Biotechnology / 인트론바이오 / 048530 / KRX:048530
Source: KRX statistical information